AIThis post was created with the assistance of artificial intelligence (AI).

TL;DR

A U.S. analysis of commercial insurance claims found that the share of women starting a GLP-1 medication within six months after delivery rose from 0.08% in early 2018 to 1.9% by early 2025. In late 2024, only 18.3% of initiators had type 2 diabetes; the study could not establish breastfeeding status or why many women started treatment.

The share of U.S. women starting a GLP-1 medication within six months of giving birth rose from 0.08% in early 2018 to 1.9% by early 2025, according to a claims-data analysis published in JAMA. The increase was especially marked among women with type 2 diabetes, but by the second half of 2024 most new postpartum users did not have that diagnosis, raising questions about prescribing patterns and the limited evidence on use after pregnancy.

Before you orderOffer from Amazon

Get workout gear delivered free with Prime

  • Fast, free delivery on millions of items
  • Prime Video, Amazon Music and more included
  • Member-only deals all year
Start your free Prime trial Free trial for eligible customers · Cancel anytime
As an affiliate, we earn on qualifying purchases.

Researchers led by Sih-Ting Cai, PhD, of the University of Southern California’s Schaeffer Center for Health Policy & Economics, examined commercial insurance claims for 911,908 women and 1,104,417 deliveries. They counted a postpartum start when a woman had at least one pharmacy claim for a GLP-1 medication within six months of delivery. The overall share increased more than 20-fold over the study period, from 0.08% to 1.9%; that comparison reflects the reported figures for those two points in time.

Among women with type 2 diabetes, the share starting a medication within six months of delivery rose from 2.3% to 16.9%. Yet in the second half of 2024, the largest reported subgroup of initiators—40.4%—had overweight or obesity, while 20.7% had no recorded diagnosis before delivery, 20.6% had gestational diabetes and 18.3% had type 2 diabetes. These figures describe the mix of initiators, not the likelihood of starting treatment within each group.

Most starts occurred three to six months after delivery, rather than immediately after birth. The median time to a first claim was 95 days for women with type 2 diabetes and 117 days for those without a relevant diagnosis recorded before delivery. Among initiators without a qualifying pre-delivery diagnosis, 55.2% had a diagnosis recorded between delivery and their first medication claim; overweight or obesity was the most common, at 52.3%.

At a glance
reportWhen: Study covers January 2018 to March 2025…
The developmentA claims-data study in JAMA found a steep rise in postpartum GLP-1 medication initiation in the United States between 2018 and early 2025.

Postpartum Prescribing Is Spreading

The findings document a change in when and among whom GLP-1 drugs are being started. These medicines are used to treat type 2 diabetes and, for some products, obesity. A growing postpartum patient group could make the evidence about medication use after delivery more relevant to clinicians and patients, especially when treatment decisions overlap with recovery, weight changes and breastfeeding.

The study does not show that the medications caused better or worse health outcomes, nor does it establish whether each prescription was appropriate. It does show that a substantial share of recent initiators did not have type 2 diabetes recorded before delivery. That makes it useful to understand how diagnoses are documented, what clinical reasons drive prescribing and how patients are counselled about benefits and risks.

Cai told MedPage Today that “the safety evidence hasn’t kept pace” with rising use and said the gap deserves more attention. The study’s authors suggested GLP-1 drugs may have a role in treating persistent metabolic risk after pregnancy, while noting that further evidence is needed.

Products Worth Considering

Philips Sonicare DiamondClean 9300 Electric Toothbrush, 2 Brush Heads, Black

Philips Sonicare DiamondClean 9300 Electric Toothbrush, 2 Brush Heads, Black

As an affiliate, we earn on qualifying purchases.

How the Claims Study Was Built

The analysis used Merative MarketScan Commercial claims and diagnostic codes to identify live births from Jan. 1, 2018, through March 31, 2025. Participants were ages 18 to 49 and had continuous insurance enrollment for six months before and after delivery. Researchers excluded women with type 1 diabetes and those with a GLP-1 medication claim in the 180 days before delivery; diagnoses were identified from claims up to a year before birth.

Before delivery, 68.2% of women had no qualifying diagnosis recorded, 17.8% had overweight or obesity, 12% had gestational diabetes and 2% had type 2 diabetes. The authors compared the U.S. pattern with a Danish study published in JAMA the previous year, which reported rising postpartum prescriptions after semaglutide was approved for weight loss. Cai described the Danish findings as a benchmark and said the trends appeared comparable despite differences between health systems.

GLP-1 medications are generally not used during pregnancy. Reviews of research on use around pregnancy have not found an apparent increase in adverse maternal or perinatal outcomes, according to the supplied report, but experts have urged caution because the evidence remains limited. Findings about pregnancy do not resolve questions about treatment while breastfeeding or in the months after delivery.

““Postpartum GLP-1 use is likely rising even faster than our numbers show, while the safety evidence hasn’t kept pace.””

— Sih-Ting Cai, PhD, the study’s lead author, speaking to MedPage Today

Safety and Prescribing Reasons Remain Open

The claims analysis cannot determine why a clinician prescribed a drug, whether a patient took it as directed, or what health outcomes followed. A diagnosis appearing only after delivery could represent newly developed or newly documented risk, or incomplete records before birth, the authors said. Claims-based diagnoses can also misclassify patients, and the researchers could not identify whether women were breastfeeding.

The study covered people with commercial insurance, so its results may not reflect patients with public coverage or those paying out of pocket. The authors also noted that some earlier GLP-1 use could have been missed if it fell outside the 180-day pre-delivery exclusion period. The data do not capture all cash-pay telehealth prescribing or compounded formulations obtained outside conventional insurance channels.

Zite said more research is needed on safety after pregnancy and during breastfeeding, and on whether treatment affects the risk of developing type 2 diabetes after gestational diabetes. She also called for research into possible effects on mental health and concerns about encouraging rapid postpartum weight loss. These are questions raised by the experts, not harms established by this study.

Researchers Seek Broader Prescribing Data

The study authors said future work should investigate what drives prescribing among women with no diagnosis recorded before delivery, as well as trends in cash-pay telehealth and compounded products. More data on breastfeeding status, clinical indications and outcomes would help distinguish documented diagnoses from the reasons behind treatment decisions.

For now, the analysis provides a benchmark for commercially insured U.S. patients through early 2025, but does not establish how safe or effective postpartum GLP-1 use is for particular groups. Clinicians and patients will need to make decisions with that evidence gap in view while research follows prescribing and health outcomes over time.

Key Questions

How much did postpartum GLP-1 use increase?

The share of women with a GLP-1 medication claim within six months after delivery rose from 0.08% in early 2018 to 1.9% by early 2025 in the study’s commercial claims data. The study defined initiation as at least one pharmacy claim in that six-month period.

Did most recent users have type 2 diabetes?

No. In the second half of 2024, 18.3% of initiators had type 2 diabetes. The largest listed group, 40.4%, had overweight or obesity; other initiators had gestational diabetes or no diagnosis recorded before delivery.

Does this study show that postpartum GLP-1 use is safe?

No. It measured medication claims and diagnoses, not safety outcomes. Researchers could not determine breastfeeding status, and the study does not establish the safety or effectiveness of these drugs for individual postpartum patients.

When did women usually start the medication?

Most initiators started three to six months after delivery. The median time to a first claim was 95 days among women with type 2 diabetes and 117 days among those with no relevant pre-delivery diagnosis.

Source: rss

Wellness content on this site is informational and not a substitute for professional medical guidance.
You May Also Like

I Had No Idea I Had An Increased Risk Of Developing Osteoporosis Until I Tried This Free Quiz—here’s How To Check Your Bone Health

A Fit&Well report describes how the Royal Osteoporosis Society’s free online checker identified risk factors and when to seek medical advice.

8 In 10 Americans Say They’re Taking Supplements. Do They Have Benefits?

Most Americans report taking dietary supplements, but experts say the health benefits remain uncertain. New data shows high usage rates amid rising interest.

New vitamin B12 therapy shows promise against deadly brain cancer

A new vitamin B12-based treatment demonstrates potential in combating aggressive brain tumors, marking a possible breakthrough in cancer therapy.

Tonal Launches First New Colorway Amid Growth Push

Tonal’s $4,795 Tonal 2 Glacier adds a lighter finish and reflective display as the company expands its reach under CEO Todd Bartee.